Yeasts Patents (Class 530/824)
  • Patent number: 8765665
    Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: July 1, 2014
    Assignees: Baxter International Inc., University of Connecticut
    Inventors: Marc Besman, Erik Bjornson, Feroz Jameel, Ramesh Kashi, Michael Pikal, Serguei Tchessalov, John Carpenter
  • Patent number: 8709446
    Abstract: The invention features HYR1 as a vaccine target and as a prophylactic strategy for combating disseminated candidiasis.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: April 29, 2014
    Assignee: Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center
    Inventors: Yue Fu, Guanpingsheng Luo, Ashraf Ibrahim, Brad Spellberg, John Edwards, Jr.
  • Patent number: 8541008
    Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: September 24, 2013
    Assignee: Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center
    Inventors: John E. Edwards, Jr., Scott G. Filler, Donald C. Sheppard, Ashraf S. Ibrahim, Yue Fu, Bradley J. Spellberg
  • Patent number: 7429388
    Abstract: This invention provides a method for identifying strains of nontypeable Haemophilus influenzae that can be used as immunogenic compositions having specificity against a plurality of Haemophilus influenzae strains. The invention also provides compositions comprising whole cell bacteria or outer membrane protein P2 obtained from the strains for use as vaccines.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: September 30, 2008
    Assignee: The Research Foundation of State University of New York
    Inventors: Thomas Hiltke, Timothy F. Murphy, Sanjay Sethi
  • Patent number: 7070793
    Abstract: To provide a novel antigenic protein and a nucleic acid encoding the antigenic protein, which are useful for prophylaxis, treatment and diagnosis of diseases caused by fungi including Candida albicans. An antigenic protein characterized in that the antigenic protein is recognized by antiserum derived from a mammal having Candida albicans-infection resistance; and a nucleic acid encoding an antigenic protein which is recognized by antiserum derived from a mammal having Candida albicans-infection resistance.
    Type: Grant
    Filed: September 28, 1998
    Date of Patent: July 4, 2006
    Assignee: Takara Bio, Inc.
    Inventors: Kazutoh Takesako, Shigetoshi Mizutani, Masahiro Endo, Junko Ogawa, Takashi Okado, Ikunoshin Kato
  • Patent number: 7067138
    Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface protein, Als1p, is a downstream effector of the filamentation regulatory pathway and is regulated by Efg1p. Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene product from the ALS1 gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.
    Type: Grant
    Filed: November 18, 2000
    Date of Patent: June 27, 2006
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: John E. Edwards, Jr., Scott G. Filler, Donald C. Sheppard, Ashraf S. Ibrahim, Yue Fu, Bradley J. Spellberg
  • Patent number: 6987173
    Abstract: A process for the preparation of biologically active somatotropin from inclusion bodies of a recombinant host cell containing an inactive form of said somatotropin protein comprises the steps of: (a) contacting the inclusion bodies with an aqueous alcohol solution at an alkaline pH to solubilize said protein; and (b) bringing the solubilized protein into contact with a mild oxidizing agent to refold and form intramolecular disulfide bonds between cysteine residues of said protein.
    Type: Grant
    Filed: January 12, 2001
    Date of Patent: January 17, 2006
    Assignee: LG Chemical Limited
    Inventors: Yong-Jun Lee, Hong-Kyun Lee, Kyuboem Han
  • Patent number: 6953684
    Abstract: The present invention provides a microorganism for the production of 1,3-propanediol from a variety of carbon sources in an organism capable of 1,3-propanediol production and comprising a) at least one gene encoding a dehydratase activity; b) at least one gene encoding a glycerol-3-phosphatase; and c) at least one gene encoding protein X. The protein X may be derived from a Klebsiella or Citrobacter gene cluster. The recombinant microorganism may further comprise d) at least one gene encoding a protein having at least 50% similarity to a protein selected from the group consisting of protein 1 (SEQ ID NO:60 or SEQ ID NO:61), of protein 2 (SEQ ID NO:62 or SEQ ID NO:63) and of protein 3 (SEQ ID NO:64 or SEQ ID NO:65) from Klebsiella or Citrobacter.
    Type: Grant
    Filed: November 13, 1997
    Date of Patent: October 11, 2005
    Assignee: Genencor International, Inc.
    Inventors: Nigel Dunn-Coleman, Maria Diaz-Torres, Matthew W. Chase, Donald Trimbur
  • Publication number: 20020032157
    Abstract: The invention provides a method of inhibiting ectopic calcification in an individual. The method consists of administering to the individual a therapeutically effective amount of osteopontin or a functional fragment thereof.
    Type: Application
    Filed: December 7, 1998
    Publication date: March 14, 2002
    Inventors: CECILIA M. GIACHELLI, SUSIE STEITZ
  • Patent number: 6348577
    Abstract: The present invention provides a protein regulating the sensitivity of fungus to an antimycotic aureobasidin, a gene coding for this protein, the use thereof, an antibody for the protein and the use thereof. The invention is useful in the diagnosis and treatment for diseases including mycoses. The invention also provides a novel chromosome integration vector capable of imparting a novel selective marker of a drug resistance to a fungal transformant, a transformant transformed with this vector and a process for producing the same. In particular, it provides a protein capable of imparting the resistance to aureobasidin and acting as a selective marker and a DNA coding for the same.
    Type: Grant
    Filed: October 7, 1999
    Date of Patent: February 19, 2002
    Assignee: Takara Shuzo Co., Ltd.
    Inventors: Takashi Okado, Kazutoh Takesako, Ikunoshin Kato
  • Patent number: 6030618
    Abstract: The present invention relates to immunogenic complexes of heat shock proteins (hsp) noncovalently bound to exogenous antigenic molecules which when administered to an individual elicit specific immunological responses in the host. Methods of prevention and treatment of cancer and infectious disease are provided.
    Type: Grant
    Filed: September 10, 1996
    Date of Patent: February 29, 2000
    Assignee: Fordham University
    Inventor: Pramod K. Srivastava
  • Patent number: 6022949
    Abstract: A gene associated with sensitivity to the antimycotic agent, aureobasidin A, has been isolated. The gene can be detected in a variety of cell types, and variant forms of the gene have been identified in mutant yeast strains. The proteins encoded by these genes are useful in diagnosing and treating mycoses.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: February 8, 2000
    Assignee: Takara Shuzo Co., Ltd.
    Inventors: Takashi Okado, Kazutoh Takesako, Ikunoshin Kato
  • Patent number: 5980891
    Abstract: The invention relates to novel Schizosaccharomyces-specific proteins and their antibodies. These proteins and antibodies can be used for identifying the yeast genus Schizosaccharomyces.
    Type: Grant
    Filed: November 18, 1994
    Date of Patent: November 9, 1999
    Inventors: Michael Broker, Johann Hock
  • Patent number: 5969098
    Abstract: The invention is directed to compounds having the following sequences: Leu Val Leu Leu Lys Lys Leu Met Lys Lys Tyr Lys Lys Leu Lys Lys Leu Gly Gly Leu as set forth in SEQ. ID. No. 1; Leu Leu Leu Leu Lys Leu Leu Leu Lys Lys Asn Pro Lys Leu Lys Lys Leu Ile Gly Val as set forth in SEQ. ID. No. 2; Leu Leu Leu Leu Lys Lys Leu Leu Lys Leu Met Asn Leu Leu Lys Lys Leu Gly His Tyr as set forth in SEQ. ID. No. 3; and Lys Lys Ile Lys Glu Lys Tyr Asp Lys Met Lys Lys as set forth in SEQ. ID. No. 4.
    Type: Grant
    Filed: June 6, 1997
    Date of Patent: October 19, 1999
    Assignee: CyberChemics, Inc.
    Inventor: Andrew Marsh Brittain
  • Patent number: 5955286
    Abstract: A receptor for an insulin-like polypeptide is purified from yeast membranes. This "insulin receptor-like protein" has a structure analogous to that of the mammalian insulin receptor. The insulin receptor-like protein of Saccharomyces cerevisiae is a heterotetrameric glycoprotein. The protein has two polypeptide types, a first polypeptide which binds insulin and has an apparent molecular weight of 135,000 to 145,000 daltons and a second polypeptide which has an apparent molecular weight of 90,000 to 95,000 daltons and is phosphorylated on tyrosine in response to binding of insulin by said first polypeptide. The first and second polypeptides are joined by disulfide linkage. The protein requires a divalent metal ion for tyrosine autophosphorylation in response to binding of insulin. The yeast insulin receptor-like protein binds human insulin with a dissociation constant of K.sub.d =8.times.10.sup.-10 M and binds human insulin-like growth factor 1 with a K.sub.d =4.times.10.sup.-10 M.
    Type: Grant
    Filed: July 22, 1997
    Date of Patent: September 21, 1999
    Assignee: The State University of New Jersey
    Inventor: Maureen A. McKenzie
  • Patent number: 5869290
    Abstract: The invention provides caYAE1 polypeptides and DNA (RNA) encoding such caYAE1 and a procedure for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing such caYAE1 for the treatment of infection, particularly fungal infections. Antagonists against such caYAE1 and their use as a therapeutic to treat infections, particularly fungal infections are also provided. Further provided are diagnostic assays for detecting diseases related to the presence of caYAE1 nucleic acid sequences and the polypeptides in a host. Also provided are diagnostic assays for detecting polynucleotides encoding caYAE1 and for detecting the polypeptide in a host.
    Type: Grant
    Filed: November 21, 1996
    Date of Patent: February 9, 1999
    Assignee: SmithKline Beecham Corporation
    Inventors: Kathryn Belinda Freeman, Richard Oakley Nicholas, George Pietro Livi
  • Patent number: 5866361
    Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: February 2, 1999
    Assignees: Institut Pasteur, Universite Pierre et Marie Curie
    Inventors: Bernard Dujon, Andre Choulika, Arnaud Perrin, Jean-Francois Nicolas
  • Patent number: 5801034
    Abstract: This invention provides a method for killing cells in fermentation mixtures in order to prepare the fermentation mixture for processing to recover or extract a desired product from the fermentation mixture. A preferred method of this invention comprises in either order, adjusting the pH of the fermentation mixture to a value equal to or less than about two pH units below the pK.sub.a of the compatible organic acid using a mineral acid, and adding a sufficient amount of a compatible organic acid and/or organic acid salt to the mixture to effect a substantially complete cell kill. The method of this invention is useful for killing microorganisms such as yeast, bacteria or fungi in any culture or fermentation mixture and is particularly useful in systems where it is desired to kill the cells without lysing them.
    Type: Grant
    Filed: December 14, 1994
    Date of Patent: September 1, 1998
    Assignee: Genencor International
    Inventors: Virgil B. Lawlis, Jr., Henry G. Heinsohn, Enrique F. Baliu
  • Patent number: 5717070
    Abstract: The present invention is directed to a family of phospholipid binding and transporting proteins, a method for preparing same from fungi, and their use in cosmeticology, the agri-foodstuffs industry and pharmacology Phospholipid proteins are capable of binding, transporting and/or rearranging lipids between membranes, optionally in combination with active principles. Furthermore, the phospholipid proteins are hydrophobic and acidic, have a molecular weight of under 50 kDa, and may be prepared from a non-toxic filamentous fungus capable of developing on a lipid-enriched medium, particularly from raw extracts of fungi.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: February 10, 1998
    Assignee: Institut National de la Recherche Agronomique-Inra
    Inventors: Eric Record, Laurence Lesage, Didier Marion, Bernard Cahagnier, Daniel Richard-Molard, Marcel Asther
  • Patent number: 5591587
    Abstract: Monoclonal receptors raised to immunogenic polyeptides whose amino acid residue sequences correspond to sequences of oncoprotein ligands are disclosed, as are method for the production of those receptors and products and methods that utilize them. The monoclonal receptors bind both to the oncoprotein ligand to a portion of which the polypeptide corresponds in sequence, and to the immunogenic polypeptide to which the receptors were raised.
    Type: Grant
    Filed: August 23, 1994
    Date of Patent: January 7, 1997
    Assignee: The Scripps Research Institute
    Inventor: Henry L. Niman
  • Patent number: 5401830
    Abstract: A receptor for an insulin-like polypeptide is purified from yeast membranes. This "insulin receptor-like protein" has a structure analogous to that of the mammalian insulin receptor. The insulin receptor-like protein of Saccharomyces cerevisiae is a heterotetrameric glycoprotein. The protein has two polypeptide types, a first polypeptide which binds insulin and has an apparent molecular weight of 135,000 to 145,000 daltons and a second polypeptide which has an apparent molecular weight of 90,000 to 95,000 daltons and is phosphorylated on tyrosine in response to binding of insulin by said first polypeptide. The first and second polypeptides are joined by disulfide linkage. The protein requires a divalent metal ion for tyrosine autophosphorylation in response to binding of insulin. The yeast insulin receptor-like protein binds human insulin with a dissociation constant of K.sub.d =8.times.10.sup.-10 M and binds human insulin-like growth factor 1 with a K.sub.d =4.times.10.sup.-10 M.
    Type: Grant
    Filed: October 5, 1992
    Date of Patent: March 28, 1995
    Assignee: The State University of New Jersey
    Inventor: Maureen A. McKenzie
  • Patent number: 5378814
    Abstract: The entire genome of the hepatitis D virus has been shown to be a circular single-stranded RNA of 1679 bases. Several open reading frames in both the genomic and complementary strands indicate possible protein products. The products encoded in one open reading frame. ORF5, are identified as vital polypeptides p24.sup..delta. and p27.sup..delta., of which the nuclear .delta. antigens in HDV infected liver is comprised. These products, as well as others encoded in ORFs 1, 2, 6, and 7 are produced in recombinant expression systems. The ORF5 products, in particular, are useful for HDV diagnosis and vaccines.
    Type: Grant
    Filed: July 9, 1992
    Date of Patent: January 3, 1995
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Kang-Sheng Wang, Qui-Lim Choo, Amy J. Weiner, Lacy R. Overby
  • Patent number: 5378621
    Abstract: This invention provides a method for killing fungal cells without lysing in fermentation processes in order to prepare the fermentation mixture for processing to recover or extract an extracellularly expressed enzyme from the fermentation mixture. A preferred method of this invention comprises adjusting the pH of the fermentation mixture to less than 2.79 using a mineral acid, then adding sufficient acetic acid to the mixture to affect a substantially complete cell kill in mixture. A salt of the acetic acid can be used. The organic acid or salt can be added, then the pH adjusted to the desired level. Other organic acids can be used, in which case the pH of the mixture is adjusted to the pK.sub.a of the selected organic acid before the organic acid is added to the mixture.
    Type: Grant
    Filed: May 7, 1993
    Date of Patent: January 3, 1995
    Assignee: Genencor, Inc.
    Inventors: Virgil B. Lawlis, Jr., Henry G. Heinsohn, Enrique F. Baliu
  • Patent number: 5356874
    Abstract: Disclosed herein is purified isolated angiogenic factor, isolated from Live Yeast Cell Derivitive. Also disclosed herein are methods to treat mammals suffering from wounds or burns comprising administering the angiogenic factor and pharmaceutical formulations for use in the methods.
    Type: Grant
    Filed: February 22, 1993
    Date of Patent: October 18, 1994
    Assignee: State of Oregon acting by and through the Oregon State Board of Higher Education on behalf of the Oregon Health Sciences University
    Inventor: J. Peter Bentley
  • Patent number: 5304542
    Abstract: The invention features a method for inhibiting proliferation of osteoblasts in a mammal in need of such inhibition. The method entails administering PF4. PF4 can be used to treat both diseases characterized by primary changes in osteoblastic cell function/activity (e.g., ossifying fibroma and fibrous dysplasia, osteoblastoma and osteoid osteoma, and osteosarcoma) and diseases or systemic conditions affecting bone in which abnormal osteoblastic cell function/activity is a secondary effect (e.g., acromegaly, hypercalcemia, primary or secondary hyperparathyroidism, hyperthyroidism, osteoporosis, or Paget's disease of bone). In addition, PF4 may be used to treat diseases associated with localized changes in bone metabolism in which abnormal osteoblastic cell function/activity contributes to pathogenic bone changes.
    Type: Grant
    Filed: August 28, 1992
    Date of Patent: April 19, 1994
    Assignee: University of Louisville Research Foundation, Inc.
    Inventor: Dimitris N. Tatakis
  • Patent number: 5238925
    Abstract: Disclosed herein is purified isolated angiogenic factor, isolated from Live Yeast Cell Derivative. Also disclosed herein are methods to treat mammals suffering from wounds or burns comprising administering the angiogenic factor and pharmaceutical formulations for use in the methods.
    Type: Grant
    Filed: May 9, 1990
    Date of Patent: August 24, 1993
    Assignee: The State of Oregon Acting by and through The State Board of Higher Education on Behalf of the Oregon Health Sciences University
    Inventor: J. Peter Bentley
  • Patent number: 5217956
    Abstract: An amphiphilic ion-channel forming peptide and a toxic anion are employed as a pharmaceutical.
    Type: Grant
    Filed: October 29, 1991
    Date of Patent: June 8, 1993
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Michael Zasloff, Wallace H. Steinberg
  • Patent number: 5128450
    Abstract: The present invention provides a pharmaceutical compositions comprising as active ingredients certain truncated purified human IL-3(Pro.sup.8 Asp.sup.15 Asp.sup.70) analog proteins expressed by transformed yeast of the species Saccharomyces cerevisiae, which when administered to a primate do not result in detectable urticaria.
    Type: Grant
    Filed: June 30, 1989
    Date of Patent: July 7, 1992
    Inventors: David L. Urdal, Helmut M. Sassenfeld
  • Patent number: 5109117
    Abstract: A method for the solubilization and naturation of somatotropin from refractile bodies produced by r-DNA technology wherein the refractile bodies are dissolved in an aqueous solution comprising a chaotropic agent such as urea or guanidine hydrochloride and a soluble organic alcohol such as isopropanol or benzyl alcohol. The solubilized protein is exposed to mild oxidation for a time sufficient to allow the protein to form disulfide bonds and refold to its native conformation. The presence of the alcohol suppresses the formation of somatotropin dimers and aggregates and results in higher yields of the desirable monomeric form of the protein.
    Type: Grant
    Filed: June 26, 1990
    Date of Patent: April 28, 1992
    Assignee: Monsanto Company
    Inventor: Sa V. Ho
  • Patent number: 5102989
    Abstract: Recombinant hepatitis B virus surface proteins produced in recombinant host cells are rapidly and efficiently purified from either cell extracts in a high pH buffer, or from heated whole cells at neutral pH. The host cell extracts or whole cells are heat treated, cooled and in the case of high pH extract, the pH is reduced. The surface proteins are then absorbed onto wide pore silica followed by elution and concentration. This method eliminates the requisite introduction of protease inhibitors, stabilizes the surface protein and improves product yield.
    Type: Grant
    Filed: March 15, 1991
    Date of Patent: April 7, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Robert D. Sitrin, Dennis J. Kubek
  • Patent number: 5093118
    Abstract: A cell wall protein of the fungus B. dermatitidis is isolated and purified. The protein is readily recognized by serum antibodies from animals having blastomycosis. The protein antigen can be labelled to provide an assay for detection of the disease, it can be used to stimulate specific lymphocyte response and thereby provide another assay for detection of the disease, it can be used to produce an immune response to B. dermatitidis, or it can be used to create antibodies to the protein.
    Type: Grant
    Filed: September 14, 1989
    Date of Patent: March 3, 1992
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Bruce S. Klein, Jeffrey M. Jones
  • Patent number: 5032676
    Abstract: An analog human colony stimulating factor (hCSF) is disclosed, comprising a mutant amino acid sequence which is substantially homologous to the native sequence of an hCSF having at least one N-glycosylation site, wherein the mutant sequence comprises at least one amino acid substitution, deletion or insertion inactivating the N-glycosylation site.
    Type: Grant
    Filed: October 14, 1986
    Date of Patent: July 16, 1991
    Assignee: Immunex Corporation
    Inventors: Michael Deeley, Virginia L. Price, David Urdal
  • Patent number: 5026828
    Abstract: Recombinant hepatitis B antigen bound to yeast membranes in yeast expression systems is rapidly purified by subjecting the membrane bound protein to agents that release undesired proteins, followed by agents that release the recombinant hepatitis B antigen.
    Type: Grant
    Filed: December 1, 1988
    Date of Patent: June 25, 1991
    Assignee: Merck & Co., Inc.
    Inventor: Shigeko Yamazaki
  • Patent number: 5023323
    Abstract: A method for the solubilization and naturation of somatotropin from refractile bodies produced by r-DNA technology wherein the refractile bodies are dissolved in an aqueous solution comprising a chaotropic agent such as urea or guanidine hydrochloride and a soluble surfactant such as sodium dodecylsulfate. The solubilized protein is exposed to mild oxidation for a time sufficient to allow the protein to form disulfide bonds and refold to its native conformation. The presence of the surfactant suppresses the formation of somatotropin dimers and aggregates and results in higher yields of the desirable monomeric form of the protein.
    Type: Grant
    Filed: September 12, 1990
    Date of Patent: June 11, 1991
    Assignee: Monsanto Company
    Inventor: Sa V. Ho
  • Patent number: 5023320
    Abstract: A process is provided for the purification of a proteinaceous physiologically active substance having antitumor activity, which is induced by administering to a rabbit at least one substance having a capacity for stimulating reticuloendothelial system and then injecting endotroxin from a Gram-negative bacterium into the rabbit. The process comprises contacting a crude solution of said proteinaceous physiologically active substance with a basic anion exchanger to have said physiologically active substance adsorbed on the anion exchanger, eluting the adsorbed physiologically active substance, and subjecting the eluate containing said physiologically active substance to gel filtration with a gel suitable for separation of a substance with a molecular weight in the range of 30,000 to 70,000. The purified preparation of said physiologically active substance thus obtained may be used as an antitumore agent for the treatment of malignant tumors.
    Type: Grant
    Filed: July 14, 1988
    Date of Patent: June 11, 1991
    Assignee: Sloan-Kettering Institute For Cancer Research
    Inventors: Katsuyuki Haranaka, Lloyd J. Old, Elizabeth C. Richards, Barbara Williamson
  • Patent number: 5019391
    Abstract: A composition for the treatment of the skin comprises a fraction of a mechanically obtained lysate of yeast cultures of the species Saccharomyces cerevisiae. The translation system contained in the compositions of the invention are obtained by lysing cultures of Saccharomyces cerevisiae. The application of such composition, in any suitable form, such as a cream, ointment, gel or the like, to skin promotes protein biosynthesis by the skin cells so that the metabolism of the extracellular matrix of the skin is restored to the physiologically correct balance and the skin is revitalized.
    Type: Grant
    Filed: August 23, 1988
    Date of Patent: May 28, 1991
    Assignee: HEYL Chemisch-parmazeutische Fabrik GmbH & Co KG
    Inventors: Thomas Bunte, Wolfgang Parr, Eduard Heyl
  • Patent number: 5011915
    Abstract: Methods of purifying recombinant surface antigen of hepatitis B virus are disclosed. In one protocol, purification is achieved by selective extraction of the antigen from yeast membranes, followed by solubilization with urea and dithiothreitol.
    Type: Grant
    Filed: October 26, 1987
    Date of Patent: April 30, 1991
    Assignee: Merck & Co., Inc.
    Inventor: Shigeko Yamazaki
  • Patent number: 4918166
    Abstract: Fusion proteins comprise a77 first amino acid sequence and a second amino acid sequence. The first amino acid sequence is derived from a retrotransposon or an RNA retrovirus and confers on the fusion protein the ability to assemble into particles; an example is the product of the YTA gene of the yeast retrotransposon Ty. The second amino acid sequence is an HIV antigen. So particles formed of the fusion proteins may be useful in vaccines or in diagnostic or purification applications.
    Type: Grant
    Filed: October 26, 1987
    Date of Patent: April 17, 1990
    Assignee: Oxford Gene Systems Limited
    Inventors: Alan J. Kingsman, Susan M. Kingsman, Sally E. Adams
  • Patent number: 4870159
    Abstract: An analysis of LEU3, a leucine-specific regulatory locus encoding a factor for control of RNA levels of a group of leucine-specific genes, is provided.DNA sequence analysis of a clone of LEU3 shows that it contains an open reading frame of 886 amino acids. There are three regions of particular interest: a cluster of acidic amino acids that are located in the C-terminal half of the coding region, a region with a repeated cysteine motif, and a region of partial homology with MATalpha2. A LEU3-dependent DNA binding activity is demonstrated to interact with homologous portions of the 5'-region of LEU1 and LEU2.
    Type: Grant
    Filed: March 6, 1987
    Date of Patent: September 26, 1989
    Assignee: Massachusetts Institute of Technology
    Inventors: Philip M. Friden, Paul R. Schimmel
  • Patent number: 4769238
    Abstract: The present invention relates to synthesis of HBsAg in yeast. Yeast expression vectors comprising a yeast promoter, ADHl, have been constructed. The region of the HBV genome coding for the S-protein, excluding a possible 163 amino acid presequence, has been transferred to the yeast expression vector.Using the described yeast vector, the successful synthesis of HBsAg by yeast has been achieved. The product is antigenic (reactive with anti-HBsAg), and a substantial portion is found associated with particles identical in electron microscopic appearance to those found in the serum of HBV-infected patients and in Alexander cells but having a smaller particle size diameter. The HBsAg synthesized by yeast has identical sedimentation behavior to purified, naturally-occurring HBsAg particles purified from Alexander cells as measured by sucrose gradient sedimentation.
    Type: Grant
    Filed: December 12, 1985
    Date of Patent: September 6, 1988
    Assignee: The Regents of the University of California
    Inventors: William J. Rutter, Pablo D. T. Valenzuela, Benjamin D. Hall, Gustav Ammerer
  • Patent number: 4767714
    Abstract: A method for the preparation of pure yeast chromatin for isolation of p20 polypeptide includes breaking yeast cells in a buffer solution and separating the released chromatin. The chromatin is purified through sucrose, solubilized by an enzymatic digestion and the supernatant solution is loaded on a linear sucrose gradient 5-30% in a buffer solution. The p20 polypeptide is extracted from the sucrose gradient fraction by a buffer solution comprising sodium chloride at a concentration in the range of 0.15-5 M and preferably in the range of 0.35 M to 2.0 M.
    Type: Grant
    Filed: July 11, 1985
    Date of Patent: August 30, 1988
    Assignee: Technion Research & Development Foundation Ltd.
    Inventor: Channa Shalitin
  • Patent number: 4665158
    Abstract: Dehydrated protein materials are treated with gaseous HCl without temperature control, the reaction temperature being susceptible to reach, momentarily, 150.degree. C. Then the material thus treated is degassed and, after drying, a non hygroscopic powder usable in the food industry or in the pharmaceutical industry is obtained.
    Type: Grant
    Filed: May 30, 1985
    Date of Patent: May 12, 1987
    Assignee: Battelle Memorial Institute
    Inventors: Jean-Michel Armanet, Claude Giddey, Jean-Pierre Sachetto